Alteco LPS Adsorber: the newest addition to best practice medical treatment for patients with COVID-19 in ICU care
Too fast. Too furious.
COVID-19 patients in ICU are experiencing increased levels of endotoxin also known as lipopolysaccharides or LPS which are responsible for provoking severe immune response called cytokine storms that can lead to life-threatening conditions including endotoxemia, sepsis, blood clotting, pneumonia, renal failure, organ failure, and even death.
Shelter from the storm
By removing LPS in the bloodstream, it may be possible to calm these cytokine storms to avoid further damage to vital organs and tissues. LPS removal treats endotoxemia even when patients have ever-increasing antibiotic resistance.
Introducing Alteco LPS Adsorber
The Alteco LPS Adsorber offers ICU teams an innovative and effective tool to complement best practice medical treatment for patients suffering from heightened immune response from LPS induced cytokine storms.
The Alteco LPS Adsorber is a medical device that adsorbs LPS from the blood. The removal of LPS turns down the exacerbated immune response, helping to stabilize the patient.
Innovative patented technology adsorbs LPS molecules in the bloodstream during haemoperfusion.
Anti-inflammatory cytokines, antibiotics and other complement treatment remain in the blood.
Simple and easy to use
Extracorporeal circulation machine with an air-trap and monitoring equipment for blood flow and pressure is required.
· Set-up in minutes
· Safe, low-risk device
· No side effects
· No serious adverse effects
· No known contraindications
Further reading – COVID-19
Observations in COVID-19 similar to the immune response in sepsis: bacterial endotoxin mediates proinflammatory signaling, activates the innate immune system through and “leads to overproduction of pro-inflammatory cytokines”.
In the absence of a bacterial infection, antibiotic treatment can cause release of endotoxin, triggering endotoxemia and over-production of pro-inflammatory cytokines - an antibiotic-induced inflammatory storm.
Binding and clearing endotoxins from circulation could be an appropriate intervention in the fight against COVID-19. 90% of patients with severe pulmonary forms of COVID-19 had increased endotoxin levels. Comorbidities of COVID-19 are connected via viral–bacterial interactions, initiated by translocation of bacterial products such as endotoxin from the gut into circulation. Increased levels of endotoxin are found in diabetes, obesity, cardiovascular diseases, older individuals but are lower in women.
"Sepsis occurs in response to an infection. When sepsis is not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. Patients who are critically ill with severe COVID-19 and other infectious diseases are at higher risk of developing and dying from sepsis."
Extracorporeal therapies represent an option for preventing organ damage in particular for COVID-19 patients and where pharmacological alternatives are lacking. Extracorporeal techniques have a possible role in “restoring a balanced immune response by eliminating/deactivating inflammatory mediators”.
Nearly 60% of COVID-19 patients in ICU had secondary bacterial infections - most commonly respiratory infections from gram-negative bacteria. “The dysregulated immune response may be associated with a high risk of developing secondary bacterial infection.”